dibozane: alpha adrenergic blockader, used mainly as a research tool; minor descriptor (77-85); on-line & Index Medicus search PIPERAZINES; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 94342 |
| CHEMBL ID | 3248389 |
| SCHEMBL ID | 11854599 |
| MeSH ID | M0263044 |
| Synonym |
|---|
| piperazine,4-bis(1,4-benzodioxan-2-ylmethyl)- |
| nsc30786 |
| mcn-181 |
| wln: t66 bo eoj c1- at6n dntj d1- ct66 bo eoj |
| 7762-32-5 |
| piperazine,4-bis[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]- |
| dibozane |
| nsc-30786 |
| dibozan |
| 1,4-benzodioxan-2-ylmethyl)piperazine |
| 1,4-bis(1,4-benzodioxan-2-yl-methyl)piperazine |
| piperazine, 1,4-bis((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)- |
| piperazine, 1,4-bis(1,4-benzodioxan-2-ylmethyl)- |
| nsc 30786 |
| 1,4-bis(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)piperazine |
| 1,4-bis(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)piperazine |
| nsc_94342 |
| bdbm81457 |
| cas_7762-32-5 |
| CHEMBL3248389 |
| SCHEMBL11854599 |
| 1,4-bis[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]piperazine |
| DTXSID30998840 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1135352 | Competitive antagonist activity at alpha-adrenergic receptor in New Zealand rabbit aorta assessed as inhibition of methoxamine-induced contraction incubated for 1 hr | 1977 | Journal of medicinal chemistry, Jul, Volume: 20, Issue:7 | Absolute configuration of glycerol derivatives. 4. Synthesis and pharmacological activity of chiral 2-alkylaminomethylbenzodioxans, competitive alpha-adrenergic antagonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||